Cancer Stem Cell News Volume 12.37 | Sep 20 2023

    0
    131







    2023-09-20 | CSCN 12.37


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 12.37 – 20 September, 2023
    TOP STORY

    KMT2A Associates with PHF5A-PHF14-HMG20A-RAI1 Subcomplex in Pancreatic Cancer Stem Cells and Epigenetically Regulates Their Characteristics

    Targeting the protein subcomplex in pancreatic cancer stem cells with a KMT2A-WDR5 inhibitor attenuated their self-renewal capacity, cell viability, and in vivo tumorigenicity.
    [Nature Communications]

    Full Article
    Explore virtual support and resources to stay productive and connected with your field.
    PUBLICATIONSRanked by the impact factor of the journal

    Fibrin Stiffness Regulates Phenotypic Plasticity of Metastatic Breast Cancer Cells

    Investigators cultured circulating tumor cells-like DU4475 triple negative breast cancer cells in mechanically tunable 3D fibrin hydrogel scaffolds. They showed that fibrin hydrogels supported DU4475 cell growth, resulting in spheroid formation.
    [Advanced Healthcare Materials]

    Abstract

    A Novel TOX3-WDR5-ABCG2 Signaling Axis Regulates the Progression of Colorectal Cancer by Accelerating Stem-Like Traits and Chemoresistance

    ABCG2 was found to be markedly up–regulated in colorectal cancer (CRC) CSCs expansion and chemo–resistant CRC tissues and closely associated with CRC recurrence.
    [PLOS Biology]

    Full Article

    Extracellular Vesicle-Carried GTF2I from Mesenchymal Stem Cells Promotes the Expression of Tumor-Suppressive FAT1 and Inhibits Stemness Maintenance in Thyroid Carcinoma

    The effects of bone marrow mesenchymal stem cell-derived extracellular vesicles enriched with GTF2I were evaluated on the epithelial–to–mesenchymal transition and stemness maintenance in thyroid carcinoma.
    [Frontiers Of Medicine]

    Abstract

    Ubiquitin-Specific Peptidase 5 Facilitates Cancer Stem Cell-Like Properties in Lung Cancer by Deubiquitinating β-Catenin

    Phenotypic effects of ubiquitin-specific peptidase 5 on the CSC-like properties and metastasis were examined by in vitro sphere formation assay, migration assay, invasion assay, and in vivo xenografted animal models.
    [Cancer Cell International]

    Full Article

    Clinical Significance of Porphyromonas gingivalis Enriching Cancer Stem Cells by Inhibiting Programmed Cell Death Factor 4 in Esophageal Squamous Cell Carcinoma

    Scientists investigated the functional mechanism by which Porphyromonas gingivalis (Pg) promoted esophageal squamous cell carcinoma chemoresistance and malignancy through inhibiting PDCD4 and enriching CSCs.
    [ACS Infectious Diseases]

    AbstractGraphical Abstract

    Pan Cancer Characterization of Genes Whose Expression has been Associated with LINE-1 Antisense Promoter Activity

    Hub long interspersed nuclear element-1 (LINE01) antisense promoter-associated genes CENPU and MCM2 showed a correlation with immune infiltration, clinical T stage, and cancer stemness in pan-cancer.
    [Mobile DNA]

    Abstract

    Cancer Stem Cells of Esophageal Adenocarcinoma are Suppressed by Inhibitors of TRPV2 and SLC12A2

    Researchers examined the expression profiles of ion transport-related molecules in the CSCs of esophageal adenocarcinoma.
    [Annals Of Surgical Oncology]

    Abstract

    MPZL1 Suppresses the Cancer Stem-Like Properties of Lung Cancer Through β-Catenin/TCF4 Signaling

    Scientists explored the influence of myelin protein zero-like protein 1 (MPZL1) on the stem-like properties of cancer cells and the underlying mechanism in lung adenocarcinoma.
    [Functional & Integrative Genomics]

    Abstract
    Nominate a colleague to be featured in the Scientist Spotlight!
    REVIEWS

    The Emerging Role of the Gut Microbiome in Cancer Cell Plasticity and Therapeutic Resistance

    The authors document the critical role of the gut microbiota on the therapeutic efficacy of existing anticancer drugs by altering the cancer plasticity.
    [Cancer And Metastasis Reviews]

    Abstract
    INDUSTRY AND POLICY NEWS

    Revolution Medicines Doses First Patient in Phase I/Ib Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

    Revolution Medicines, Inc. announced the first patient was dosed in its Phase I/Ib monotherapy clinical trial of RMC-9805, an oral, covalent, mutant-selective KRASG12D(ON) Inhibitor designed to treat patients with cancers driven by the KRASG12D mutation.
    [Revolution Medicines, Inc. ]

    Press Release
    FEATURED EVENT

    AACR Special Conference: Advances in Breast Cancer Research

    October 19 – 22, 2023
    San Diego, California, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Associate- Cancer Biology

    Baylor College of Medicine – Houston, Texas, United States

    Open Rank Faculty – Pharmacology

    University of Houston – Houston, Texas, United States

    Clinical / Non-Clinical Senior Lecturer – Experimental Medicine

    King’s College London – London, England, United Kingdom

    Principal Investigators – Molecular Cell Science

    Chinese Academy of Sciences – Shanghai, China

    Assistant Professor – Cancer, Cardiovascular and Metabolic Health, or Brain, Mind, and Behavior

    Northwestern University – Chicago, Illinois, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter